Trial Profile
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 17 Feb 2012 Actual patient number (27) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Actual initiation (Jun 2011) date added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.